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Abstract: Chemotherapy is a common type of preoperative neoadjuvant treatment and postoperative adjuvant or 
palliative therapy for many different types of malignancies. Certain chemotherapeutic agents can induce bizarre 
epithelial atypia that mimics malignancy. Unfamiliarity with these changes could potentially cause confusion with a 
neoplastic or infectious process. The endometrium is one of the few sites where chemotherapy-induced epithelial 
atypia has not been appreciated. We identified four patients with marked cytologic atypia of the endometrial glandu-
lar epithelium from the surgical pathology files of Severance Hospital. The histopathologic features, immunostaining 
results and medical records of these patients were reviewed. All patients underwent hysteroscopic examination 
with endometrial curettage for investigation of vaginal bleeding. They had previously undergone chemotherapy for 
uterine cervical cancer (n=1), rectal cancer (n=2) and myelodysplastic syndrome (n=1). The chemotherapy regi-
mens included alkylating agents (busulfan, cyclophosphamide, ifosfamide, cisplatin, and oxaliplatin), pyrimidine 
antagonists (capecitabine, decitabine, and 5-fluorouracil), taxanes (paclitaxel), and topoisomerase inhibitors (irino-
tecan and etoposide). On histopathological examination, the atypical epithelial changes included marked nuclear 
enlargement and pleomorphism, a degenerative-looking chromatin pattern, abundant microvacuolated cytoplasm, 
and preservation of the nuclear/cytoplasmic ratio. This study demonstrates that certain chemotherapeutic agents 
may cause bizarre, reactive atypia of the endometrial glandular epithelium. These changes should not be inter-
preted as neoplastic or infectious in nature. An awareness of prior exposure to cytotoxic agents and a familiarity with 
the nature and distribution of these bizarre alterations is essential to avoid misinterpretation of the morphologic 
features and prevent unnecessary treatment.
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Introduction
Chemotherapy uses medicine as a definitive 
treatment or as an adjuvant therapy to destroy 
and weaken malignant cells in the body, and it 
is known for its propensity to induce cytologic 
atypia in epithelial cells [1], including bizarre 
atypical epithelial alterations [2]. Although the 
lungs and urinary bladder have drawn the most 
attention as targets of cytotoxic effects [3, 4], 
such atypical changes can be widespread 
throughout the body. Chemotherapy-induced 
epithelial atypia has been noted in many organs 
and tissues such as the sinonasal tract [2], 
esophagus [5], stomach [5-7], small intestine 
[5, 8], uterine cervix [4, 9] and breast [10, 11]. 
Epithelial alterations associated with chemo-
therapeutic agents include marked nuclear 
enlargement, pleomorphism and hyperchroma-
sia, and intracytoplasmic and/or intranuclear 
inclusion-like vacuoles, potentially causing pa- 
thologists to consider a diagnosis of a malig-
nancy or viral-induced cytopathic effect.
We recently encountered some cases in which 
chemotherapy-induced epithelial atypia was ini-
tially thought by several observers to be a 
malignancy, but was later related to prior che-
motherapy once an appropriate history and 
associated medical conditions were consid-
ered. We herein demonstrate chemotherapy-
induced epithelial atypia observed in the endo-
metrium of patients with epithelial or hema- 
tologic malignancies. These cases highlight the 
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endometrium as yet another possible target of 
the cytotoxic effects of chemotherapeutic 
agents. To our knowledge, the endometrium is 
one of the few sites where chemotherapy-in- 
duced epithelial atypia has not been docu- 
mented.
Patients and methods
Study group
Four patients with atypical epithelial alterations 
in their endometrial curettage specimens were 
identified from the surgical pathology files of 
the Severance Hospital, Yonsei University Co- 
llege of Medicine between 2006 and 2015. All 
patients underwent hysteroscopic examination 
with endometrial curettage for presumed non-
neoplastic disease of the endometrium. This 
study was reviewed and approved by the In- 
stitutional Review Board at Severance Hospital, 
Yonsei University College of Medicine, Seoul, 
Republic of Korea (2015-1413-001).
Histopathological evaluation
For each case, tissue had been fixed in 10% 
neutral-buffered formalin, embedded in paraf-
fin and stained with hematoxylin and eosin. A 
representative tissue block of each case was 
selected for immunohistochemical staining. 
Routinely processed tissue sections from the 
endometrial curettage specimens were evalu-
ated for a variety of histopathological findings 
associated with chemotherapy-induced cyto-
toxic effects. These included the location and 
distribution of the atypical changes, nuclear 
size and the degree of pleomorphism, hyper-
chromaticity and chromatin quality, appear-
ance of nucleoli, nuclear/cytoplasmic ratio, pre- 
sence and location of mitoses and atypical 
mitotic figures, and the quality of the cytoplas-
mic content. Clinical information was obtained 
from the medical records or by communication 
with the referring pathologist or the patients’ 
physicians in order to determine their oncologic 
history, treatment regimen, associated medical 
diseases and the condition prompting endome-
trial curettage.
Immunohistochemical evaluation
Formalin-fixed, paraffin-embedded tissue sec-
tions were deparaffinized and rehydrated with a 
xylene and alcohol solution. Immunohisto- 
chemical staining used the Ventana Benchmark 
XT automated staining system (Ventana Me- 
dical Systems, Inc., Tucson, AZ, USA) or Dako 
Omnis (Dako, Agilent Technologies, Inc., Car- 
pinteria, CA, USA) according to the manufac-
turer’s instructions. Antigen retrieval used Cell 
Conditioning Solution (CC1; Ventana Medical 
Systems, Inc.) or EnVision FLEX Target Retrieval 
Solution, High pH (Dako, Agilent Technologies, 
Inc.). Sections were incubated with primary 
antibodies (Table 1). After chromogenic visual-
ization using ultraView Universal DAB Detection 
Kit (Ventana Medical Systems, Inc.) or EnVision 
FLEX/HRP (Dako, Agilent Technologies, Inc.), 
slides were counterstained with hematoxylin 
and coverslipped. Appropriate positive and 
negative controls were stained concurrently to 
validate staining.
Epstein-Barr virus-encoded RNA in situ hybrid-
ization
The tissue sections obtained from the endome-
trial curettage specimens were used for 
Epstein-Barr virus (EBV)-encoded RNA in situ 
hybridization (EBER-ISH). The sections were 
deparaffinized with xylene, pretreated with pro-
teinase K for 20 min, and incubated with fluo-
rescein isothiocyanate (FITC)-conjugated EBER 
oligonucleotide probes (Novocastra Labora- 
tories) at 55°C for 2 h. The sections were rinsed 
in water and incubated with horseradish perox-
idase-conjugated anti-FITC antibody for 15 min 
before adding the chromogen to produce an 
alcohol-insoluble dark nuclear stain in EBV-
Table 1. Antibodies used for immunohistochemical staining
Antibody Source Clone Dilution
Ki-67 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA MIB-1 1:150
p16 Ventana Medical Systems, Inc., Tucson, AZ, USA E6H4 Prediluted
p53 NovoCastra Laboratories, Ltd., Newcastle upon Tyne, UK DO-7 1:300
CMV Dako, Agilent Technologies, Inc., Carpinteria, CA, USA CCH2+DDG9 1:100
HSV Dako, Agilent Technologies, Inc., Carpinteria, CA, USA Polyclonal RTU
CMV: cytomegalovirus; HSV: herpes simplex virus.
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Table 2. Summary of clinical features
Patient Age Malignancy (stage) Chemotherapy regimens  (purpose if available)
Associated  
medical problems
Gynecologic  
symptoms
Interval from  
chemotherapy to curettage
Hysteroscopic  
findings
Current 
status
Follow-up 
period
1 63 Uterine cervical cancer  
(FIGO IIB)
Paclitaxel, cisplatin, ifosfamide Septic shock,  
neutropenia
Vaginal bleeding 4 months Atrophic  
endometrium
NED 54 months
2 39 Rectal cancer  
(cT4N+M0/ypT0N0M0)
Capecitabine (NAC) None Vaginal bleeding 2 months Atrophic  
endometrium
NED 12 months
3 42 Rectal cancer  
(cT3N+M0/ypT3N1aM0)
Capecitabine (NAC); FOLFOX, FOLFIRI,  
etoposide, ifosfamide (palliative)
None Vaginal bleeding 10 months Atrophic  
endometrium
NED 17 months
4 52 Myelodysplastic syndrome  
(RAEB-2)
Decitabine; cyclophosphamide, busulfan  
(conditioning)
PBSCT, CMV  
viremia, IUD in situ
Vaginal bleeding 4 months Atrophic  
endometrium
NED 4 months
NED: no evidence of endometrial disease; NAC: neoadjuvant chemotherapy; FOLFOX: leucovorin, 5-fluorouracil and oxaliplatin; FOLFIRI: leucovorin, 5-fluorouracil and irinotecan; RAEB: refractory anemia with excess blasts; PBSCT: allogeneic 
peripheral blood stem cell transplantation; CMV: cytomegalovirus; IUD: intrauterine device.
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positive cells. We used EBV-absent lymphoid 
tissues processed using the hybridization mix-
ture without EBER oligonucleotides as negative 
controls.
Figure 1. Histopathological findings. A. Detached strips of endometrial glandular epithelium revealed atypical cells 
showing abundant, amphophilic, partly vacuolized cytoplasm and enlarged nuclei with irregular outlines and hy-
perchromasia. The nuclear/cytoplasmic ratio was not increased, because the quantity of cytoplasm was also in-
creased. A few conspicuous nucleoli were identified. B. A bizarre nucleus (red circle) was approximately five times 
larger compared to its normal counterpart. C. An endocervical gland had a few large, hyperchromatic nuclei (blue 
circle). D and E. Variable distribution of the atypical cells was observed. D. In some areas, atypical cells showing 
variable degrees of nuclear pleomorphism were distributed in a patchy fashion (green arrows). E. In other areas, 
pseudostratified atypical cells with a degenerative-looking chromatic pattern showed architectural disarray. F-H. In-
tracytoplasmic vacuolar change (red arrows) and/or intranuclear microvesiculation (blue arrows) raise the suspicion 
of viral-induced cytopathic effect.
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Results
Clinical findings
Table 2 summarizes the clinical features of four 
patients whose endometrial curettage speci-
mens exhibited severe epithelial atypia. The 
age of the patients ranged from 39 to 63 years. 
In all patients, endometrial curettage was per-
formed to investigate vaginal bleeding. The 
contributing pathologist was initially unaware 
of a history of prior chemotherapy in either 
case. However, all patients had malignancies: 
one (Patient 1) had uterine cervical cancer, two 
(Patients 2 and 3) had rectal cancer and one 
(Patient 4) had myelodysplastic syndrome 
(MDS). Patient 1, with a history of chemothera-
py for FIGO stage IIB uterine cervical cancer, 
had developed septic shock and neutropenia. 
Patients 2 and 3, with histories of neoadjuvant 
chemotherapy for stage III rectal cancer, under-
went low anterior resection of the colon. Patient 
3 also received postoperative palliative chemo-
therapy. Patient 4, with a history of conditioning 
treatment with alkylating agents prior to alloge-
neic peripheral blood stem cell transplantation 
for MDS, developed acute cutaneous graft-ver-
sus-host disease and cytomegalovirus (CMV) 
viremia. Moreover, she had an intrauterine 
device inserted.
There was significant variation in the chemo-
therapeutic treatment agents among individual 
patients. Nevertheless, three of four patients 
had been exposed to single or multiple alkylat-
ing agents (busulfan, cyclophosphamide, ifos-
famide, cisplatin or oxaliplatin), and three pa- 
tients had been exposed to single pyrimidine 
antagonists (capecitabine, 5-fluorouracil or 
decitabine). In addition, one patient with rectal 
cancer (Patient 3) received postoperative palli-
ative treatment with combination regimens 
including topoisomerase inhibitors (irinotecan 
and etoposide). The time interval from chemo-
therapy to endometrial curettage ranged from 
2 to 10 months.
Hysteroscopic examination revealed an atro-
phic endometrium that was not easily indented 
by pressure and looked thin and relatively 
homogeneous. In two patients, a small amount 
of fluid was identified within the endometrial 
cavity. However, no evidence of cystic changes, 
polyps, irregular thickening, or mass-like lesi- 
ons was identified. Ultrasonography findings 
were similar to the hysteroscopic ones in all 
cases. No patient had endometrial thickening, 
a mass-like lesion, cavitary distortion, abnor-
mal echogenicity, or adnexal abnormalities. The 
endometrial thickness was less than 5 mm in 
all patients.
Clinical follow-up information was available in 
all patients. The follow-up period ranged from 4 
to 54 months. All patients were still alive at the 
end of the follow-up period. Patient 3 devel-
oped vaginal bleeding once again 7 months 
after the curettage, but a repeat curettage was 
not performed. The remaining three patients 
reported no gynecologic symptoms during the 
post-curettage period. 
Histopathological findings
Under the light microscope, endometrial curet-
tage specimens demonstrated severely enlar- 
ged nuclei showing hyperchromasia and pleo-
morphism with irregular and misshapen out-
lines, while the nuclear/cytoplasmic ratio was 
not increased (Figure 1A). The enlarged nuclei 
were three to seven times their normal size 
(Figure 1B). Despite prominent hyperchroma-
sia, the chromatin pattern showed homoge-
neous basophilic staining without coarse 
clumping. The distribution of the atypical cells 
was variable. They were present in the endome-
trial glandular epithelium in all cases, whereas 
the endometrial stromal cells or endothelial 
cells did not exhibit significant cytologic atypia. 
Some of the endocervical glands also con-
tained atypical cells with irregularly contoured, 
hyperchromatic nuclei (Figure 1C). In some 
areas, the epithelial atypia involved the endo-
metrial glands in a discontinuous, patchy fash-
ion (Figure 1D). In other areas, the atypical 
cells were distributed more densely and occu-
pied the full thickness of the epithelium (Figure 
1E). In addition to the nuclear alterations, epi-
thelial atypia consisted of occasional conspicu-
ous nucleoli, either single or multiple, a normal 
or slightly low nuclear/cytoplasmic ratio, and 
abundant, basophilic cytoplasm with microve-
siculation. Some of the atypical cells contained 
intracytoplasmic (Figure 1F) and intranuclear 
(Figure 1G, 1H) inclusion-like vacuoles, raising 
the suspicion of a viral-induced cytopathic 
effect. In particular, CMV endometritis associ-
ated with CMV viremia was strongly suspected 
in Patient 4. However, an inflammatory infiltra-
tion of lymphocytes and plasma cells, a charac-
teristic feature of CMV endometritis, was not 
identified. No evidence of an invasive tumor 
was identified. No mitotic figures or abnormal 
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ones were discovered despite a thorough 
search and serial sectioning. Necrosis was not 
observed. 
Immunohistochemical findings
In all patients, immunohistochemical staining 
for herpes simplex virus (HSV) and CMV, p53, 
p16 and Ki-67 was performed. The atypical 
cells were negative for HSV (Figure 2A) and 
CMV (Figure 2B). p53 nuclear staining was 
patchy and weak, indicating a wild-type TP53 
gene (Figure 2C). p16 expression was absent 
(Figure 2D). Ki-67 stained less than 5% of the 
nuclei of the atypical cells (Figure 2E). We also 
Figure 2. Immunohistochemical findings. Lack of (A) HSV and (B) CMV immunoreactivity excluded the possibility of 
a viral-induced cytopathic effect. (C) Patchy nuclear staining for p53 indicated the absence of the TP53 mutation. 
(D) The patchy expression pattern of p16 expression in atypical cells (blue arrows) was the same as that in normal 
endometrial glandular epithelium (red arrows). (E) Ki-67 proliferation index was low (less than 5%) in the atypical 
epithelial cells. (F) EBER-ISH did not reveal EBV infection in the atypical epithelial cells.
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performed EBER-ISH to investigate whether 
EBV infected the atypical cells; no atypical cells 
exhibited EBV positivity (Figure 2F).
Discussion
A variety of benign epithelial proliferations and 
metaplastic changes within the endometrium 
may cause pathologists to consider a diagnosis 
of malignancy. Common conditions, including 
syncytial papillary change, eosinophilic cell 
change, hobnail cell metaplasia, clear cell ch- 
ange, and Arias-Stella reaction, result in a dif-
ferential diagnosis of carcinoma. In this study, 
we add another lesion to the list: chemothera-
py-induced epithelial atypia. We found some 
specific references to this phenomenon occur-
ring in diverse organs and tissues, but there 
was no available data on the effects of chemo-
therapeutic agents on the endometrium. Ini- 
tially, our cases were mistaken for premalig-
nant neoplastic processes or definitive malig-
nancies. Unlike dysplasia or carcinoma, how-
ever, the chemotherapy-induced epithelial aty- 
pia was not associated with significantly in- 
creased mitotic activity or atypical mitoses. 
Even though there was bizarre nuclear atypia 
with marked cellular enlargement and pleomor-
phism exceeding those seen in malignancy, 
preservation of nuclear/cytoplasmic ratio, ab- 
undant vacuolated cytoplasm, a degenerative-
looking chromatin pattern and a low prolifera-
tive index did not support the diagnosis of car-
cinoma. Pathologists should be aware of 
chemotherapy-related alterations in order to 
avoid an erroneous diagnosis of malignancy. 
These changes were probably caused by an 
arrest in nuclear division due to the metabolic 
effects of the cytotoxic drugs [12]. The benign 
nature of the atypical cells was supported by 
the lack of an increase in their nuclear DNA 
content [13].
The association of epithelial atypia and expo-
sure to cytotoxic drugs is very compelling. 
However, at least in this study, it may be impos-
sible to clarify that any single specific agent 
causes epithelial alterations in the endometri-
um. All except one patient had been exposed to 
more than one cytotoxic drug in complex combi-
nations, and treatment regimens varied across 
patients. The chemotherapeutic agents used in 
our patients were alkylating agents, pyrimidine 
antagonists, taxanes and topoisomerase inhib-
itors. The alkylating agents are known as one of 
the most common and direct causes of non-
neoplastic, reactive epithelial atypia in many 
organ systems such as the upper and lower 
respiratory tract, gastrointestinal tract, uterine 
cervix, urothelium and skin. Previous studies 
have demonstrated that the bizarre, pleomor-
phic cells observed in cytology and/or biopsy 
specimens obtained from alkylating agent-
treated patients display anaplastic changes 
exceeding those of a carcinoma, and most 
importantly, the nuclear/cytoplasmic ratio is 
preserved and there is a microvacuolar and 
vesicular appearance of abundant, amphophil-
ic or eosinophilic cytoplasm [2, 7, 9, 12, 14-18]. 
There is agreement in the literature that cyclo-
phosphamide is the drug most strongly associ-
ated with epithelial atypia administered either 
alone or, most often, with busulfan. 5-fluoroura-
cil, a pyridine analogue that acts as an antime-
tabolite to uracil [7, 19], interferes with DNA 
synthesis by blocking the conversion of deoxy-
uridylic acid to thymidylic acid [19]. Because of 
the damaged DNA, one can speculate that 
regenerating cells may go through a phase of 
genotypic and phenotypic atypia in their path-
way to repair [7]. Regarding the possible effect 
of paclitaxel on epithelial cells, skin biopsy 
specimens from patients receiving taxane ther-
apy exhibit numerous apoptotic and mitotic fig-
ures including atypical forms [20]. Epithelial 
cells of the gastrointestinal tract mucosa dis-
play extensive apoptosis and numerous mitotic 
figures and ring mitoses, indicating mitotic 
arrest [21]. Accordingly, one can speculate that 
the histopathological findings we observed in 
the specimen obtained from Patient 1, who 
received combination chemotherapy with pacli-
taxel and two alkylating agents, may be attrib-
utable to the latter rather than the former. In 
addition, the presence of epithelial atypia in the 
specimen obtained from Patient 2, who re- 
ceived neoadjuvant chemotherapy with ca- 
pecitabine for rectal cancer, raises the possibil-
ity that capecitabine may cause epithelial atyp-
ia by itself. The possible correlation between 
topoisomerase inhibitors and chemotherapy-
induced epithelial atypia also exists. Further 
investigations are necessary in order to clarify 
the effects of capecitabine and/or topoisomer-
ase inhibitors on non-neoplastic epithelial cells.
The morphologic changes induced by chemo-
therapeutic agents can mimic a neoplastic pro-
cess. Indeed, many studies have cautioned 
against misinterpreting chemotherapy-induced 
epithelial atypia as carcinoma [2, 6, 7, 9, 17, 
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20, 21]. Several factors may render the endo-
metrium particularly susceptible to erroneous 
interpretation of chemotherapy-induced atypia. 
First, the endometrium has not drawn much 
attention as a target of such cytotoxic effects, 
and few pathologists anticipate such altera-
tions at this site. Second, when these changes 
do come across the microscope of an unwary 
pathologist, first-time encounters are likely to 
occur inopportunely during an intraoperative 
frozen section. Frozen section artifacts tend to 
accentuate structural distortion and cytologic 
atypia while obscuring subtle differences be- 
tween chemotherapy-induced atypia and true 
malignancies.
We noted that Patient 4 with MDS developed 
CMV viremia after receiving conditioning treat-
ment with busulfan and cyclophosphamide for 
peripheral blood stem cell transplantation. In 
this patient, the epithelial atypia was initially 
misinterpreted as CMV endometritis. Con- 
current CMV viremia might contribute to the 
wrong diagnosis. A thorough review of histolog-
ic slides confirmed that there was no definitive 
evidence of deeply amphophilic to basophilic 
intranuclear inclusions, which are characteris-
tic of CMV infection. The absence of immunore-
activity for CMV and lymphoplasmacytic infiltra-
tion did not support the diagnosis of CMV 
endometritis. In addition, in this patient, it may 
be also possible that dislocation of an intra-
uterine device caused vaginal bleeding.
In conclusion, chemotherapy, alone or as part 
of a multimodal treatment for various malig-
nancies, is popular. It is crucial for pathologists 
to be aware of the full spectrum and consider-
able variability of morphological changes in- 
duced by chemotherapeutic agents. Reco- 
gnition of these histopathological changes, 
combined with the knowledge of the patient’s 
history of prior chemotherapy, allows the exam-
ining pathologist to strongly consider chemo-
therapy-induced epithelial atypia as the correct 
diagnosis in cases of bizarre epithelial atypia. 
Whenever there is a suspicion that the atypical 
changes may be attributable to chemotherapy, 
a history of this therapy should be specifically 
sought. An awareness of prior exposure to cyto-
toxic agents, and a familiarity with the nature 
and distribution of these changes is essential 
to avoid misinterpretation of the morphologic 
features and prevent unnecessary treatment. 
Statistics and sample size limitations should be 
discussed.
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